Clinical & translational oncology

• 

  Año 2025, Vol. 27, Número 4

  • REVIEW ARTICLE

    • STAS: New explorations and challenges for thoracic surgeons

      Teng Xia, Qian Yuan, Shi gui Xing

      • Resumen

      págs. 1345-1355

      

    • Roles of LncRNA ARSR in tumor proliferation, drug resistance, and lipid and cholesterol metabolism

      Zhicheng Li, Dan Wang, Xiaojun Zhu

      • Resumen

      págs. 1356-1365

      

    • High‑dose vitamin C as a metabolic treatment of cancer: a new dimension in the era of adjuvant and intensive therapy

      Xin Wang, Jia He, Minmin Sun, Shiwan Wang, Jinxiu Qu, Hanping Shi, Benqiang Rao

      • Resumen

      págs. 1366-1382

      

    • Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu‑PSMA‑617 radioligand‑therapy in prostate cancer

      Ovidio Fernández Calvo, José Lorenzo Muñoz Iglesias, Estephany Abou Jokh Casas, Aurea Molina Díaz, Urbano Anido Herranz, Javier Casas Nebra, Lucía García Bernardo, Sara Martínez Breijo, Martin Lázaro Quintela, Gloria Muñiz García, Sergio Vázquez Estévez

      • Resumen

      págs. 1383-1397

      

    • Focal adhesion kinase‑mediated interaction between tumor and immune cells in the tumor microenvironment: implications for cancer‑associated therapies and tumor progression

      Louis Boafo Kwantwi, Theophilus Tandoh

      • Resumen

      págs. 1398-1405

      

    • Emerging immunologic approaches as cancer anti‑angiogenic therapies

      Mohammadreza Azimi, Mahdokht Sadat Manavi, Maral Afshinpour, Roya Khorram, Reza Vafadar, Fatemeh Rezaei, Danyal Arabzadeh, Sattar Arabzadeh, Nasim Ebrahimi, Amir Reza Aref

      • Resumen

      págs. 1406-1425

      

    • Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC

      Georgia Gomatou, Andriani Charpidou, Peifeng Li, Nikolaos Syrigos, Ioannis Gkiozos

      • Resumen

      págs. 1426-1437

      

    • Cancer stem cells in meningiomas: novel insights and therapeutic implications

      Wireko Andrew Awuah, Adam Ben Jaafar, Simran Karkhanis, Princess Afa Nkrumah Boateng, Jonathan Sing Huk Kong, Krishitha Meenu Mannan, Vallabh Shet, Matan Bone, Allswell Naa Adjeley Boye, Sruthi Ranganathan, Muhammad Hamza Shah, Toufk Abdul Rahman, Oday Atallah, Shahzeb Imran

      • Resumen

      págs. 1438-1459

      

  • CLINICAL GUIDES IN ONCOLOGY

    • SEOM‑GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024)

      César Serrano García, Marta Arregui Valles, Irene Carrasco García, Nadia Hindi Muñiz, Javier Martínez Trufero, Jerónimo Martinez Garcia, Aurea Molina Díaz, Ana Paisán Ruiz, Raúl Sánchez González, Maria Ángeles Sala Gonzalez

      • Resumen

      págs. 1460-1471

      

  • RESEARCH ARTICLE

    • Application of random survival forest to establish a nomogram combining clinlabomics‑score and clinical data for predicting brain metastasis in primary lung cancer

      Zhongxiang Shi, Yixin Chen, Aoyu Liu, Jingya Zeng, Wenlin Xie, Xin Lin, Yangyang Cheng, Huimin Xu, Jialing Zhou, Shan Gao, Chunyuan Feng, Hongxia Zhang, Yihua Sun

      • Resumen

      págs. 1472-1483

      

    • Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive‑stage small cell lung cancer treated with frst‑line chemoimmunotherapy

      Elena Herranz Bayo, Luis Enrique Chara Velarde, Javier Guillermo Cassinello Espinosa, Vicente Gimeno Ballester, Ángel Artal Cortés, Alba Moratiel Pellitero, Arancha Alcácera López, Fátima Navarro Expósito, Blanca Riesco Montes, Manuel Clemente Andujar

      • Resumen

      págs. 1484-1492

      

    • The efcacy and safety of neoadjuvant immunochemotherapy in resectable stage I‑III non‑small cell lung cancer: a systematic review and network meta‑analysis

      Bo Li, Yujia Gu, Weixing Zhao, Zirui Li, Wanjing Guo, Xinxin Lu, Jun Jiang

      • Resumen

      págs. 1493-1505

      

    • Prediction of EGFR‑TP53 genes co‑mutations in patients with lung adenocarcinoma (LUAD) by 18F‑FDG PET/CT radiomics

      Shuheng Li, Yujing Hu, Congna Tian, Jiusong Luan, Xinchao Zhang, Qiang Wei, Xiaodong Li, Yanzhu Bian

      • Resumen

      págs. 1506-1515

      

    • Identifying patients who beneft more from perioperative immunotherapy combinations for resectable non‑small cell lung cancer based on clinical and molecular characteristics: a meta‑analysis of randomized clinical trials

      Yunchang Meng, Hedong Han, Suhua Zhu, Chuling Li, Huijuan Li, Zhaofeng Wang, Ranpu Wu, Yimin Wang, Qingfeng Zhang, Yanzhuo Gong, Yong Song, Tangfeng Lv, Hongbing Liu

      • Resumen

      págs. 1516-1528

      

    • NRI and SIRI are the optimal combinations for prognostic risk stratifcation in patients with non‑small cell lung cancer after EGFR‑TKI therapy

      Xia Liu, Peipei Wang, Guolong Liu

      • Resumen

      págs. 1529-1538

      

    • Construction and clinical signifcance of prognostic risk markers based on cancer driver genes in lung adenocarcinoma

      Yazhou Su, Tingting Huo, Yanan Wang, Jingyan Li

      • Resumen

      págs. 1539-1557

      

    • PCMT1 as a prognostic marker in breast cancer

      Patryk Rogaczewski, Michał Janiak, Jędrzej Borowczak, Łukasz Szylberg

      • Resumen

      págs. 1558-1568

      

    • Investigation of TMEM41A's function in breast cancer prognosis and its connection to immune cell infltration

      Fan Fan, Ruiwen Feng, Xuxin Zhang, Xiabin Li, Yan Tang

      • Resumen

      págs. 1569-1585

      

    • Prevalence and impact of metabolic associated fatty liver disease in non‑metastatic breast cancer women at initial diagnosis: a cross‑sectional study in China

      Zhi‑yu Jiang, Xin‑yu Liang, Lei Hu, Liang Ran, Rui‑ling She, Chen‑yu Ma, Jun‑han Feng, Jing‑yu Song, Zhao‑xing Li, Xiu‑quan Qu, Bai‑qing Peng, Kai‑nan Wu, Ling‑quan Kong

      • Resumen

      págs. 1586-1596

      

    • Potential prognostic biomarker SERPINA12: implications for hepatocellular carcinoma

      Huan Yang, Panpan Kong, Songyu Hou, Xiaogang Dong, Imamumaimaitijiang Abula, Dong Yan

      • Resumen

      págs. 1597-1611

      

    • lncSNHG16 promotes hepatocellular carcinoma development by inhibiting autophagy

      Zhu-Jian Deng, Hao-Tian Liu, Bao Hong Yuan, Li Xin Pan, Yu-Xian Teng, Jia Yong Su, Cheng-Piao Luo, Ping Ping Guo, Jian-Hong Zhong

      • Resumen

      págs. 1612-1622

      

    • Using machine learning methods to investigate the impact of age on the causes of death in patients with early intrahepatic cholangiocarcinoma who underwent surgery

      Shiqin Song, Shixiong Song, Huarong Zhao, Shike Huang, Xinghua Xiao, Xiaobo Lv, Yuehong Deng, Yiying Tao, Yanlin Liu, Ke Su, Shansha Cheng

      • Resumen

      págs. 1623-1631

      

    • Predictors of major postoperative complications in cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

      Ana Tejedor, Marina Vendrell, Lana Bijelic, Jaume Tur Martínez, Marina Bosch, Graciela Martínez Pallí

      • Resumen

      págs. 1632-1641

      

    • Long‑term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors

      Barbara Kiesewetter, Friedrich Franz Pfüger, Philipp Melhorn, Peter Mazal, Markus Raderer

      • Resumen

      págs. 1642-1652

      

    • The HALP score as a prognostic factor in metastatic biliary cancer

      Ismet Seven, Irfan Karahan, Fahriye Tuğba Köş, Dogan Bayram, Serhat Sekmek, Selin Aktürk Esen

      • Resumen

      págs. 1653-1657

      

    • Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes

      Jian Zhao, Hongxing Guo, Chenxuan Wu, Hongsheng Guo

      • Resumen

      págs. 1658-1667

      

    • Evaluation of immune‑checkpoint molecules in dMMR/pMMR colorectal cancer by multiplex immunohistochemistry

      Sergei Sergeevich Naumov, Liubov Alexandrovna Tashireva, Nadezhda Valerievna Krakhmal, Sergey Vladimirovich Vtorushin

      • Resumen

      págs. 1668-1680

      

    • MCT4 is an independent prognostic factor and afects immune cell infltration in patients with colorectal liver oligometastases

      Jiahua He, Weihao Li, Jiayu Wang, Xiaojun Wu, Weili Zhang, Junzhong Lin, Binyi Xiao, Long Yu, Leen Liao, Song Wang, Weifeng Wang, Yuguang Lin, Xuanlin Hong, Yue Xing, Zhizhong Pan, Jianhong Peng

      • Resumen

      págs. 1681-1694

      

    • Effect of smoking on the recurrence and progression of non‑muscle‑invasive bladder cancer

      Chaohu Chen, Guangrui Fan, Pan Li, Enguang Yang, Suoshi Jing, Yibo Shi, Yuwen Gong, Luyang Zhang, Zhiping Wang

      • Resumen

      págs. 1695-1711

      

    • TET3 is expressed in prostate cancer tumor‑associated macrophages and is associated with anti‑androgen resistance

      Qiu ju Wei, Hai qi Liang, Yao wen Liang, Zu xin Huang

      • Resumen

      págs. 1712-1727